Status:
UNKNOWN
Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®
Lead Sponsor:
Versailles Hospital
Conditions:
Leukemia, Myeloid, Acute
Eligibility:
All Genders
18+ years
Brief Summary
Gemtuzumab Ozogamicin/Mylotarg® (GO) is a conjugate of a derivative of calicheamicin a potent antitumor anthracycline antibiotic linked to a recombinant humanized antibody against the CD33 antigen. Pi...
Eligibility Criteria
Inclusion
- Patient more than 18 year old;
- De novo or secondary leukemia.
- Refractory to standard intensive chemotherapy (defined by the association of anthracycline and cytarabine, at different doses) or in first relapse.
- Treated with GO from January 2012 to December 2016.
Exclusion
- Previous treatment with GO
- AML type 3
- More than 1 relapse
Key Trial Info
Start Date :
November 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2019
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03287128
Start Date
November 1 2017
End Date
March 1 2019
Last Update
January 24 2018
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
C.H.U. d'Amiens - Hôpital Sud
Amiens, France
2
C.H.U. d'Angers
Angers, France
3
HIA Percy
Clamart, France
4
Hôpital Henri Mondor
Créteil, France